Project Grant R43AG085842
Award Date
8/1/24
Completion Date
7/31/25
Dollars Obligated
$515K
Federal Agency
National Institute on Aging
Awardee
Neuroindx (XS6TCKK96DR6)
Federal Grant Program
93.866
Assistance Type
Project Grant
Place of Performance
Torrance, CA 90501, USA
Similar Awards
This $500,000 Project Grant was awarded on September 15, 2024 by the National Institute on Aging (CFDA 93.866 Aging Research program) to Neucyte Inc., a minority-owned small business specializing in advanced biomedical research and development. The funding will support the development of a miniaturized "mini-brain" microphysiological system (MPS) platform using Alzheimer's disease (AD) patient-derived cells. The goal is to create a scalable, reproducible in vitro brain model that can...
The National Institute on Aging (NIA), under the Federal Aging Research program (CFDA 93.866), awarded a $245,148 project grant to Eyenexo LLC to develop an automated rodent behavior testing system for non-invasively assessing early-stage Alzheimer's disease (AD). The project aims to develop a behavior biomarker that can differentiate AD from normal aging by studying defensive behaviors triggered by looming stimuli, which are linked to early AD pathology in the midbrain region. The 2-year...
The National Institute on Aging (NIA), under the Aging Research Federal Grant Program (CFDA 93.866), awarded a $472,695 project grant to 3D Bioanalytix, Inc. to develop a blood-based diagnostic test for early detection and differentiation of neurodegenerative diseases such as Alzheimer's and Parkinson's. The project leverages the company's Covalent Protein Painting (CPP) platform technology to detect and identify misfolded protein aggregates that characterize these diseases. This novel...
This Project Grant award from the National Institute on Aging (CFDA 93.866 - Aging Research) provides $994,436.00 to Transchromix LLC to develop novel brain-penetrant drugs for treating Alzheimer's disease (AD). The key products and services being delivered include: Discovering a noncanonical, translation regulatory function of the histone methyltransferase G9A in AD pathogenesis using a chromatin-activity-based chemoproteomic (ChAC) approach to dissect AD heterogeneity. Deducing the mechanism...
Phenovista Biosciences LLC received a $749,700 Project Grant award from the National Institutes of Health's National Institute on Aging under the Aging Research program (CFDA 93.866) for the period February 1, 2021 through August 31, 2021. The award will support Phenovista's development, validation, and commercialization of a suite of high-throughput, high-content functional assays using human induced pluripotent stem cell-derived microglia models for Alzheimer's disease drug screening. The...
This $4,618,216 Cooperative Agreement (U01AG088051) awarded by the National Institute on Aging (CFDA 93.866 - Aging Research) supports the development of CNDR-51997, a novel microtubule-stabilizing drug candidate for the treatment of Alzheimer's disease (AD) and related neurodegenerative tauopathies. The primary objectives are to advance CNDR-51997 through IND-enabling studies and submit an Investigational New Drug (IND) application to the FDA. This late-stage research builds on prior NIH-funded...
This $500,000 Project Grant awarded by the National Institute on Aging (CFDA 93.866 Aging Research) will support Sxrna Technologies, Inc. in developing an organoid toolkit for Alzheimer's disease (AD) and Alzheimer's-disease-related dementias (ADRD). The company aims to create a platform for identifying senescent cells in living tissue, which can provide insights into the aging process and enable high-throughput drug screening in complex 3D tissue models. Specifically, the grant will fund...
This Project Grant award from the National Institute on Aging (CFDA 93.866 - Aging Research) will fund the development of a novel Alzheimer's disease therapeutic using targeted nanoparticles. The $504,732 award to Aphios Corp, a minority-owned biotechnology company, will support two phases of research. In Phase I, the company will nanoencapsulate an anti-CCR5 drug in targeted and non-targeted nanoparticles, characterize the formulations, and evaluate their impact on in vitro models of brain...
The National Institute on Aging (NIA) awarded a $1,512,892 Project Grant under the Aging Research program (CFDA 93.866) to 3P Biotechnologies, Inc. to develop a targeted nanoformulation delivery system for the bioactive curcuminoids, curcumin and bisdemethoxycurcumin, to treat Alzheimer's disease (AD). The Phase I project aims to optimize exosome-based formulations of these compounds and assess their biodistribution and toxicity in mice, as well as determine the efficacy of folic...
This Project Grant award from the National Institute on Aging (CFDA 93.866 - Aging Research) provides $479,375 to Florida International University to conduct research on the effect of a small molecule activator of autophagy, TPI-132, on insulin signaling, senescence, and neuropathology in mouse models of Alzheimer's disease. The goal is to optimize TPI-132 to increase its potency, brain penetration, and reduce toxicity, and then evaluate its impacts on neuronal senescence, synapses, protein...